Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

NO_LONGER_AVAILABLE

Conditions studied: Acquired Hemophilia A

In brief

To provide emergency access to OBI-1 for patients with Acquired Hemophilia and a serious bleeding episode who do not have access to an active clinical study site associated with the OBI-1-301 study.

Key facts

Study ID

NCT01968655

Run by

Baxalta now part of Shire

Last updated by the study team

2021-05-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent from participant or their legal representative.
• Participants with acquired hemophilia with autoimmune inhibitors to human factor VIII.
• Has a serious bleeding episode, as documented by the investigator.
• Be willing and able to follow all instructions and attend all study visits.
• Participants taking anti-thrombotics may be included depending on the time elapsed since taking such medications.
• Life expectancy of at least 90 days prior to the onset of the bleeding episode.

You may not qualify if…

• Hemodynamically unstable after blood transfusion, fluid resuscitation and pharmacologic or volume replacement pressor therapy.
• Has an established reason for bleeding that is not correctable.
• Bleeding episode assessed likely to resolve on its own if left untreated.
• Anti-OBI-1 inhibitor that exceeds 20 BU (prospectively or retrospectively).
• Subsequent bleeding episode at the site of the initial qualifying bleeding episode within 2 weeks following the final OBI-1 dose for the initial qualifying bleeding episode, or subsequent bleeding episode at a different site than the initial qualifying bleeding episode within 1 week following the final OBI-1 dose for the initial qualifying bleeding episode will not be considered "new" qualifying bleeding episodes.
• Prior history of bleeding disorder other than acquired hemophilia.
• Known major sensitivity (anaphylactoid reactions) to pig or hamster products.
• Use of hemophilia medication within 3 to 6 (depending on medication) hours prior to OBI-1 administration.
• Participation in any other clinical study within 30 days of the first OBI 1 treatment.
• Anticipated need for treatment or device during the study that may interfere with the evaluation.
• Abnormal baseline findings
• Inability or unwillingness to comply with the study design, protocol requirements, or the follow-up procedures.

Where it is running

• National Institutes of Health Warren G. Magnuson Clinical Center — Bethesda, Maryland, United States
• Tufts Medical Center — Boston, Massachusetts, United States
• Penn State — Hershey, Pennsylvania, United States
• Vanderbilt Hemostasis/Hemophilia Clinic — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.